Related Experiment Video
Updated: Jan 4, 2026
Scalable High Throughput Selection From Phage-displayed Synthetic Antibody Libraries
Published on: January 17, 2015
Selection of Antibody Fragments for CAR-T Cell Therapy from Phage Display Libraries
Nestor F Leyton-Castro1, Marcelo M Brigido1,2, Andrea Q Maranhão3,4
1Molecular Pathology Graduation Programme, School of Medicine, University of Brasilia, Brasilia, Brazil.
Abstract:
CAR-T cell therapy emerged in the last years as a great promise to cancer treatment. Nowadays, there is a run to improve the breadth of its use, and thus, new chimeric antigen receptors (CAR) are being proposed. The antigen-binding counterpart of CAR is an antibody fragment, scFv (single chain variable fragment), that recognizes a membrane protein associated to a cancer cell. In this chapter, the use of human scFv phage display libraries as a source of new mAbs against surface antigen is discussed. Protocols focusing in the use of extracellular domains of surface protein in biotinylated format are proposed as selection antigen. Elution with unlabeled peptide and selection in solution is described. The analysis of enriched scFvs throughout the selection using NGS is also outlined. Taken together these protocols allow for the isolation of new scFvs able to be useful in the construction of new chimeric antigen receptors for application in cancer therapy.
Insights
Researchers developed new methods to find novel single-chain variable fragments (scFv) for chimeric antigen receptors (CAR). These scFvs are crucial for CAR-T cell therapy advancements in cancer treatment.
Area of Science:
- Immunology
- Biotechnology
- Oncology
Background:
- Chimeric antigen receptor (CAR)-T cell therapy shows significant promise for cancer treatment.
- Developing novel CARs is essential to broaden the application of CAR-T cell therapy.
- The antigen-binding component of CARs is a single-chain variable fragment (scFv) that targets cancer-specific surface proteins.
Purpose of the Study:
- To discuss the utility of human scFv phage display libraries for identifying new monoclonal antibodies (mAbs) against tumor surface antigens.
- To present protocols for isolating novel scFvs for CAR construction.
Main Methods:
- Utilizing extracellular domains of surface proteins in biotinylated format as selection antigens.
- Employing elution with unlabeled peptides and selection in solution.
- Analyzing scFv enrichment using next-generation sequencing (NGS).
Main Results:
- Protocols were established for the isolation of scFvs targeting specific surface antigens.
- The described methods facilitate the identification of novel scFv binders.
Conclusions:
- The presented protocols enable the isolation of new scFvs.
- These scFvs can be utilized in constructing novel CARs for enhanced cancer therapy applications.
